Palvella Therapeutics PVLA EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Palvella Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Palvella Therapeutics's EPS (diluted)?
- Palvella Therapeutics (PVLA) reported EPS (diluted) of -$1.20 in Q1 2026.
- How has Palvella Therapeutics's EPS (diluted) changed year-over-year?
- Palvella Therapeutics's EPS (diluted) decreased by 62.2% year-over-year, from -$0.74 to -$1.20.
- What is the long-term trend for Palvella Therapeutics's EPS (diluted)?
- Over 2 years (2021 to 2025), Palvella Therapeutics's EPS (diluted) has grown at a 131.9% compound annual growth rate (CAGR), from -$0.69 to -$3.71.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.